Recent Company News

• 08:24 PM ET Apr 15, 2026
  

  Quick Take - Otsuka Holdings sell-side analyst briefing (¥10545.0000, 0)

• 09:27 AM ET Apr 10, 2026
  

  Transcript Intelligence: Otsuka Holdings Business Update Call

• 10:40 AM ET Apr 07, 2026
  

  Otsuka Holdings initiated neutral at SBI Securities Japan (¥11195.0000, 0)

• 10:41 PM ET Apr 02, 2026
  

  StreetAccount Summary: Asian stocks reaching new 52-week highs/lows (58 total)

• 04:09 PM ET Apr 02, 2026
  

  Esperion Therapeutics and Athyrium Capital Management enter into $50M Japan royalty financing to support strategic acquisition of Corstasis Therapeutics ($2.61, 0.00)

• 11:07 PM ET Apr 01, 2026
  

  StreetAccount Summary: Japan Stocks reaching new 52-week highs/lows (65 total)

• 11:06 PM ET Apr 01, 2026
  

  StreetAccount Summary: Asian stocks reaching new 52-week highs/lows (64 total)

• 02:00 PM ET Mar 30, 2026
  

  StreetAccount Summary - Private Company Weekly Recap - Week of 23-Mar

• 05:10 AM ET Mar 27, 2026
  

  Otsuka Pharmaceutical to buy Transcend Therapeutics at initial transfer price of $700M (¥111.95B) (¥11400.0000, 0)

• 02:11 AM ET Mar 27, 2026
  

  Otsuka submits application for Japanese regulatory approval of Iclusig for first-line treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia in adults (¥11350.0000, +260)